- Home
- FEBO vs BOLT Comparison
FEBO vs BOLT Comparison
Compare FEBO & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- BOLT
- Stock Information
- Founded
- FEBO 1993
- BOLT 2015
- Country
- FEBO Hong Kong
- BOLT United States
- Employees
- FEBO N/A
- BOLT N/A
- Industry
- FEBO
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- FEBO
- BOLT Health Care
- Exchange
- FEBO Nasdaq
- BOLT Nasdaq
- Market Cap
- FEBO 8.0M
- BOLT 9.4M
- IPO Year
- FEBO 2023
- BOLT 2021
- Fundamental
- Price
- FEBO $0.70
- BOLT $5.19
- Analyst Decision
- FEBO
- BOLT Buy
- Analyst Count
- FEBO 0
- BOLT 3
- Target Price
- FEBO N/A
- BOLT $47.50
- AVG Volume (30 Days)
- FEBO 431.0K
- BOLT 14.4K
- Earning Date
- FEBO 10-24-2025
- BOLT 08-14-2025
- Dividend Yield
- FEBO N/A
- BOLT N/A
- EPS Growth
- FEBO N/A
- BOLT N/A
- EPS
- FEBO N/A
- BOLT N/A
- Revenue
- FEBO $17,110,653.00
- BOLT $4,167,000.00
- Revenue This Year
- FEBO N/A
- BOLT N/A
- Revenue Next Year
- FEBO N/A
- BOLT N/A
- P/E Ratio
- FEBO N/A
- BOLT N/A
- Revenue Growth
- FEBO 11.58
- BOLT N/A
- 52 Week Low
- FEBO $0.61
- BOLT $4.59
- 52 Week High
- FEBO $8.50
- BOLT $14.36
- Technical
- Relative Strength Index (RSI)
- FEBO 41.81
- BOLT 46.64
- Support Level
- FEBO $0.68
- BOLT $4.81
- Resistance Level
- FEBO $0.76
- BOLT $5.28
- Average True Range (ATR)
- FEBO 0.11
- BOLT 0.26
- MACD
- FEBO 0.01
- BOLT 0.01
- Stochastic Oscillator
- FEBO 12.58
- BOLT 70.26
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.